4OCTOBER - 2021TECH OUTLOOKDe-risking the Preclinical Phase of Immunotherapy Drug DevelopmentIN MY OPINIONRalph Gareus, Director Business Development, The Jackson Laboratory08COVER STORY 12CXO INSIGHTSTai Nicolopoulos, Head of Marketing, SeedInvestStartups in the Coronavirus Era: The Acceleration of Online Fundraising21Michael Scholl,CEOLIQUID DRUG FORMULATION BOLSTERED BY AILeukocare AG
< Page 3 | Page 5 >